Maria Teresa Melucci

List of Publications by Year in Descending Order

36 papers	1,891 citations	19 h-index	38 g-index
38 ext. papers	2,138 ext. citations	4.8 avg, IF	3.71 L-index

#	Paper	IF	Citations
36	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. *OncoImmunology*, **2017**, 6, e1283462	7.2	21
35	Phenotype characterization of human melanoma cells resistant to dabrafenib. *Oncology Reports*, **2017**, 38, 2741-2751	3.5	16
34	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. *Journal of Investigative Dermatology*, **2016**, 136, 1917-1920	4.3	11
33	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. *Journal of the American Academy of Dermatology*, **2016**, 74, 325-32	4.5	23
32	Epidemiological and genetic factors underlying melanoma development in Italy. *Melanoma Management*, **2015**, 2, 149-163	2.1	3
31	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. *Frontiers in Oncology*, **2015**, 5, 183	5.3	62
30	The immune-related role of BRAF in melanoma. *Molecular Oncology*, **2015**, 9, 93-104	7.9	26
29	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. *Cancer Immunology, Immunotherapy*, **2014**, 63, 675-83	7.4	205
28	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. *OncoImmunology*, **2014**, 3, e28780	7.2	259
27	Unexpected distribution of cKIT and BRAF mutations among southern Italian patients with sinonasal melanoma. *Dermatology*, **2013**, 226, 279-84	4.4	31
26	Mutations in ERBB4 may have a minor role in melanoma pathogenesis. *Journal of Investigative Dermatology*, **2013**, 133, 1685-7	4.3	7
25	Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. *Oncology Reports*, **2011**, 25, 1495-502	3.5	17
24	The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients. *Annals of Oncology*, **2010**, 21, 1379-1380	10.3	5
23	NEMO-binding domain peptide inhibits proliferation of human melanoma cells. *Cancer Letters*, **2009** , 274, 331-6	9.9	29
22	Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. *Annals of Oncology*, **2008**, 19, 2092-3	10.3	8
21	Issues affecting molecular staging in the management of patients with melanoma. *Journal of Cellular and Molecular Medicine*, **2007**, 11, 1052-68	5.6	26
20	Molecular classification of patients with malignant melanoma for new therapeutic strategies. *Journal of Clinical Oncology*, **2007**, 25, e20-1	2.2	12

19	Adjuvant treatment of malignant melanoma: where are we?. *Critical Reviews in Oncology/Hematology*, **2006**, 57, 45-52	7	8
18	Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. *Melanoma Research*, **2005**, 15, 235-44	3.3	45
17	Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. *Journal of Clinical Oncology*, **2005**, 23, 7660-8	2.2	191
16	BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. *Journal of Clinical Oncology*, **2004**, 22, 286-92	2.2	47
15	Mutation analysis of candidate genes in melanoma-prone families: evidence of different pathogenetic mechanisms at chromosome 9P21. *Melanoma Research*, **2003**, 13, 571-9	3.3	10
14	Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. *Melanoma Research*, **2003**, 13, 167-70	3.3	32
13	Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. *Journal of Clinical Oncology*, **2003**, 21, 767-73	2.2	81
12	Adjuvant therapy of melanoma: whatâs new?. *Melanoma Research*, **2002**, 12, 293-6	3.3	4
11	Mobile hospital rooms to fight melanoma. *Melanoma Research*, **2001**, 11, 83-4	3.3	
10	Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Melanoma Cooperative Group. *Recent Results in Cancer Research*, **2001**, 158, 200-3	1.5	17
9	Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group. *Annals of Oncology*, **2000**, 11, 487-90	10.3	1
8	Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment. *Annals of Oncology*, **2000**, 11, 1504	10.3	4
7	Cisplatin, dacarbazine, and fotemustine plus interferon in patients with advanced malignant melanoma. *Cancer*, **2000**, 89, 2630-2636	6.4	19
6	Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. The Melanoma Cooperative Study. *British Journal of Dermatology*, **2000**, 142, 893-8	4	40
5	Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group. *British Journal of Cancer*, **2000**, 83, 1707-14	8.7	39
4	Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposiâs sarcoma. *Annals of Oncology*, **2000**, 11, 635-6	10.3	2
3	Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. *Journal of Clinical Oncology*, **1999**, 17, 304-11	2.2	102
2	Adjuvant therapy of cutaneous melanoma. *Lancet, The*, **1999**, 353, 328	40	8

1 Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma. *Melanoma Research*, **1998**, 8, 529-37 3.3 23